CD19 CAR T‐cell therapy has shown suboptimal results in CLL clinical trials and has raised concerns of CD19‐negative escape in CLL and other B‐cell malignancies. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.